Stephen Marley Launches Plant-Based CBD Personal Care Line

Dec.14.2022
Stephen Marley Launches Plant-Based CBD Personal Care Line
Stephen Marley releases plant-based Kx Family Care, featuring CBD-infused Hair and Beard Oil, Pain Relief Balm, and more.

On Monday, Grammy-winning artist Stephen Marley launched a product line called Kx Family Care, which is a plant-based CBD personal care collection that utilizes the benefits of cannabis and other herbs traditionally used in Jamaica.


The debut series features limited holiday packages containing two products: a versatile hair and beard oil, and a pain relief balm both infused with full spectrum CBD oil, known for its anti-inflammatory, antibacterial, and antioxidant properties.


These two products also contain sunflower oil, vitamin E, and linoleic acid, which have antioxidants that help protect the skin from free radical damage and maintain its natural barrier. They also contain black seed oil, sapodilla fruit extracts, and star apple, which are widely used in Jamaican culture for their regenerative properties.


For example, Jamaican black castor oil comes from the seeds of the Nigella sativa plant, which is rich in antioxidants and offers various health benefits.


Kx Family Care is a natural progression for me, due to my passion for the cannabis plant and its various uses," said founder Stephen Marley. "This brand is authentic in every way, from the natural infusion of Jamaican plants in our products, to the eco-friendly wood and glass packaging we use. Our goal is centered on family, natural health, sustainability, and respect for the many uses of the cannabis plant.


Kx Family Care is the multi-generational personal-care product branch of Kaya Lifestyle, owned and operated by Marley. Kaya Lifestyle also hosts Kaya Fest, a music and education cannabis advocacy festival.


Marley joined the CEO and co-founder Shelly O'Neill to spend three years researching and developing a plant-based, multipurpose product designed specifically for busy families. Marley believes that marijuana is just like any other useful herb. "Marijuana is an herb, like mint or sage, that can cure many diseases and provide spiritual enlightenment," Marley told the cultural magazine in 2018.


The idea for Kx Family Care arose while O'Neill and Marley were working together at Kaya Fest, a world music festival organized by Marley to promote education surrounding the various uses of the cannabis plant. The term "Kaya" is a Jamaican slang word for herb, derived from the Caribbean English word "kayakiit," meaning a type of herb.


Experience Marley's cannabis products firsthand: Kx Family Care's pop-up store will be opening on specific dates during Stephen Marley's upcoming Old Soul Tour - Unplugged 2023.


We are pleased to introduce the first all-natural, cannabis-based personal care brand that is safe and effective for the entire family," said founder Stephen Marley. "We look forward to giving our customers a firsthand experience of the Kx Family Care pop-up store at the specific date of The Old Soul Tour - Unplugged in 2023.


The company stated that the US Food and Drug Administration (FDA) does not require basic safety testing on ingredients in personal care products. These products often contain toxic ingredients that can harm the skin and hair.


The company also maintains its commitment to the environment in its packaging.


Kx Family Care aims to utilize eco-friendly materials including hemp plastic to showcase the various uses of the cannabis plant and reduce plastic waste, according to its website. Inspired by Jamaica's nickname as the "land of wood and water," the company captures the essence by using biodegradable wood and glass in its packaging. Kx also spreads love by supporting different charitable organizations every quarter with a portion of its sales revenue.


Several siblings and family members of Marley have ventured into the CBD or cannabis business, including Ziggy and Damian.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Altria Reports Full-Year 2025 Results: Revenue Down 3.1%, Cigarette Volumes Slide 10% as NJOY Takes Impairment Hit
Altria Reports Full-Year 2025 Results: Revenue Down 3.1%, Cigarette Volumes Slide 10% as NJOY Takes Impairment Hit
Altria has released its full-year 2025 results, reporting full-year net revenues of $23.279 billion, down 3.1% year over year. Domestic cigarette shipment volume fell 10% for the year. on! nicotine pouches reached a 7.7% share of the U.S. oral tobacco category in the fourth quarter. NJOY posted $21 million in net revenues in Q4, while full-year net revenues were negative $13 million (mainly due to returns and related factors).
Jan.30 by 2FIRSTS.ai
BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
British American Tobacco said 2026 will mark a return to its mid-term growth algorithm, but CEO Tadeu Marroco stressed that deliverywill depend heavily on enforcement against illicit vapour products in the United States. Speaking at the FY2025 results call, he positioned Modern Oral as the company’s primary structural growth engine, reframed accelerating cigarette declines through “poly-usage,” and reinforced capital discipline with an expanded share buyback plan.
Feb.12
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
Turning Point Brands, a U.S. nicotine and tobacco-related consumer products company, reported its fiscal 2025 fourth-quarter results: quarterly revenue was $121 million, up 29% year over year; adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) was $30 million, up 14%. Net revenue from modern oral nicotine products was $41.3 million, up 266% year over year.
Mar.03 by 2FIRSTS.ai
China Tobacco Jiangsu Industrial Patent Points to 3D-Printed Nicotine Oral Products
China Tobacco Jiangsu Industrial Patent Points to 3D-Printed Nicotine Oral Products
Jiangsu China Tobacco Industrial Co., Ltd. has disclosed a patent describing a nicotine oral formulation produced using 3D printing technology. The invention enables a three-stage nicotine release system—rapid onset, sustained delivery and long-term release—through a layered structure with varying porosity. The technology reflects growing experimentation within China Tobacco’s research system around precision nicotine delivery for modern oral products.
Mar.09
South Korean Court Strikes Down Health Levy on Vape Nicotine Liquids, Citing Disproportionate Penalties
South Korean Court Strikes Down Health Levy on Vape Nicotine Liquids, Citing Disproportionate Penalties
A Seoul court has annulled South Korea’s health-levy assessments imposed on multiple importers of nicotine liquids used for vaping. While the court agreed the nicotine could be treated as “tobacco” because it was found to be leaf-derived, it ruled the levy—stacked with other taxes and calculated on a blunt, volume-only basis—was so severe it effectively deprived businesses of the ability to operate, breaching constitutional proportionality and equality standards.
Jan.26 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11